Floatz logo

Cytosin-Arabinosid

Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Children's Oncology GroupPhase 3Active
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies cohort.

Asset / SponsorPhaseRating
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
Joanna Yi
Phase 3BBB
Daunorubicin
Princess Maxima Center for Pediatric Oncology
Phase 3BBB
THIOGUANINE ANHYDROUS
Grupo Argentino de Tratamiento de la Leucemia Aguda
Phase 3BB
ASPARAGINASE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB

View all 9 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →